Terms: = Lymphoma AND SMAD2, MADH2, 4087, ENSG00000175387, MGC34440, MGC22139, hMAD-2, MADR2, JV18-1, hSMAD2, JV18 AND Treatment
19 results:
1. treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.
Feng J; Fei Y; Gao M; Meng X; Zeng D; Zou D; Ye H; Liang Y; Sun X; Liang R; Zhou H; Wang X; Zhang H
Hematol Oncol; 2024 May; 42(3):e3268. PubMed ID: 38676394
[TBL] [Abstract] [Full Text] [Related]
2. Differential Reactivation of Cytomegalovirus and Epstein-Barr Virus in Patients with B Cell lymphoma.
Hatayama Y; Watanabe K; Ichikawa H; Kawamura K; Fukuda T; Motokura T
Viral Immunol; 2023 Oct; 36(8):520-525. PubMed ID: 37440168
[TBL] [Abstract] [Full Text] [Related]
3. Galunisertib synergistically potentiates the doxorubicin-mediated antitumor effect and kickstarts the immune system against aggressive lymphoma.
Rej A; Paladhi A; Daripa S; Sarkar D; Bhattacharyya S; Mondal I; Hira SK
Int Immunopharmacol; 2023 Jan; 114():109521. PubMed ID: 36470118
[TBL] [Abstract] [Full Text] [Related]
4. Genistein alleviates renin-angiotensin system mediated vascular and kidney alterations in renovascular hypertensive rats.
Poasakate A; Maneesai P; Potue P; Bunbupha S; Tong-Un T; Settheetham-Ishida W; Khamseekaew J; Pakdeechote P
Biomed Pharmacother; 2022 Feb; 146():112601. PubMed ID: 35062067
[TBL] [Abstract] [Full Text] [Related]
5. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell lymphoma.
Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
[TBL] [Abstract] [Full Text] [Related]
6. Knockdown of long non‑coding RNA ANRIL inhibits the proliferation and promotes the apoptosis of Burkitt lymphoma cells through the TGF‑β1 signaling pathway.
Mao S; Jin J; Li Z; Yang W
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33325535
[TBL] [Abstract] [Full Text] [Related]
7. Inhibition of Interleukin 10 Transcription through the smad2/3 Signaling Pathway by Ca
Matsui M; Kajikuri J; Kito H; Endo K; Hasegawa Y; Murate S; Ohya S
Mol Pharmacol; 2019 Mar; 95(3):294-302. PubMed ID: 30622214
[TBL] [Abstract] [Full Text] [Related]
8. Bcl-3 regulates TGFβ signaling by stabilizing Smad3 during breast cancer pulmonary metastasis.
Chen X; Cao X; Sun X; Lei R; Chen P; Zhao Y; Jiang Y; Yin J; Chen R; Ye D; Wang Q; Liu Z; Liu S; Cheng C; Mao J; Hou Y; Wang M; Siebenlist U; Eugene Chin Y; Wang Y; Cao L; Hu G; Zhang X
Cell Death Dis; 2016 Dec; 7(12):e2508. PubMed ID: 27906182
[TBL] [Abstract] [Full Text] [Related]
9. Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer.
Zhang Y; Zhang Y; Geng L; Yi H; Huo W; Talmon G; Kim YC; Wang SM; Wang J
J Biol Chem; 2016 Aug; 291(33):17405-16. PubMed ID: 27330076
[TBL] [Abstract] [Full Text] [Related]
10. Pentoxifylline Attenuates Proteinuria in Anti-Thy1 Glomerulonephritis via Downregulation of Nuclear Factor-κB and smad2/3 Signaling.
Chen YM; Chiang WC; Yang Y; Lai CF; Wu KD; Lin SL
Mol Med; 2015 Apr; 21(1):276-84. PubMed ID: 25879629
[TBL] [Abstract] [Full Text] [Related]
11. Transforming growth factor β1 (TGF-β1) suppresses growth of B-cell lymphoma cells by p14(ARF)-dependent regulation of mutant p53.
Chen G; Ghosh P; O'Farrell T; Munk R; Rezanka LJ; Sasaki CY; Longo DL
J Biol Chem; 2012 Jun; 287(27):23184-95. PubMed ID: 22621932
[TBL] [Abstract] [Full Text] [Related]
12. Distinctive mechanism for sustained TGF-β signaling and growth inhibition: MEK1 activation-dependent stabilization of type II TGF-β receptors.
Chen G; Ghosh P; Longo DL
Mol Cancer Res; 2011 Jan; 9(1):78-89. PubMed ID: 21131601
[TBL] [Abstract] [Full Text] [Related]
13. Marek's disease virus type 1 microRNA miR-M3 suppresses cisplatin-induced apoptosis by targeting smad2 of the transforming growth factor beta signal pathway.
Xu S; Xue C; Li J; Bi Y; Cao Y
J Virol; 2011 Jan; 85(1):276-85. PubMed ID: 20962090
[TBL] [Abstract] [Full Text] [Related]
14. Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma.
Nakahata S; Yamazaki S; Nakauchi H; Morishita K
Oncogene; 2010 Jul; 29(29):4157-69. PubMed ID: 20514018
[TBL] [Abstract] [Full Text] [Related]
15. Resistance to TGF-beta 1 correlates with aberrant expression of TGF-beta receptor II in human B-cell lymphoma cell lines.
Chen G; Ghosh P; Osawa H; Sasaki CY; Rezanka L; Yang J; O'Farrell TJ; Longo DL
Blood; 2007 Jun; 109(12):5301-7. PubMed ID: 17339425
[TBL] [Abstract] [Full Text] [Related]
16. Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/activin receptor-like kinase-4/5/7/smad2 signaling pathway.
Ruiz E; Redondo S; Gordillo-Moscoso A; Tejerina T
J Pharmacol Exp Ther; 2007 May; 321(2):431-8. PubMed ID: 17267584
[TBL] [Abstract] [Full Text] [Related]
17. Loss of functional transforming growth factor (TGF)-beta type II receptor results in insensitivity to TGF-beta1-mediated apoptosis and Epstein-Barr virus reactivation.
Fukuda M; Kurosaki H; Sairenji T
J Med Virol; 2006 Nov; 78(11):1456-64. PubMed ID: 16998876
[TBL] [Abstract] [Full Text] [Related]
18. Smad signal and TGFbeta induced apoptosis in human lymphoma cells.
Sebestyén A; Barna G; Nagy K; Jánosi J; Paku S; Kohut E; Berczi L; Mihalik R; Kopper L
Cytokine; 2005 Jun; 30(5):228-35. PubMed ID: 15927846
[TBL] [Abstract] [Full Text] [Related]
19. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.
Bollard CM; Rössig C; Calonge MJ; Huls MH; Wagner HJ; Massague J; Brenner MK; Heslop HE; Rooney CM
Blood; 2002 May; 99(9):3179-87. PubMed ID: 11964281
[TBL] [Abstract] [Full Text] [Related]
